Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei MSMC 39-1
- Development stage
- Phase 2
- Lead developer
- Srinakharinwirot University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Lactobacillus paracasei MSMC 39-1 (also classified as Lacticaseibacillus paracasei MSMC 39-1) is a probiotic bacterial strain originally isolated from healthy human infant feces by researchers at Srinakharinwirot University in Thailand. It exhibits potent anti-inflammatory and immunomodulatory properties, primarily through the suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-17A (IL-17A), thereby modulating the IL-23/IL-17 inflammatory axis. Developed in collaboration with Winona Feminine, the strain is utilized both as an oral probiotic (marketed under the brand Winona Probio) and as a topical postbiotic solution (derived from its cell-free supernatant). It has been clinically evaluated for the treatment of mild chronic plaque psoriasis, mild-to-moderate acne vulgaris, and metabolic syndrome, and has shown preclinical efficacy in models of alcoholic hepatitis and kidney fibrosis.
- Brand names
- Winona Probio
- Other names
- Lacticaseibacillus paracasei MSMC 39-1Lacticaseibacillus paracasei MSMC39-1Lactobacillus paracasei MSMC39-1
02
Targets
IFNG (Interferon gamma)IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Lactobacillus paracasei MSMC 39-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei MSMC 39-1.